Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary.
Masaoka
Tohru
T
Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000627:therapeutic use; D005334:Fever / Q000150:complications; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007564:Japan; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D018570:Risk Assessment; D018805:Sepsis / Q000150:complications / Q000188:drug therapy*; D005719:gamma-Globulins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D005719:gamma-Globulins; D016179:Granulocyte Colony-Stimulating Factor